Reperfusion therapy in ST-segment elevation myocardial infarction – data from a pilot registry of myocardial infarction*

Zdeněk Monhart[1], Václav Faltus[2,3], Hana Grünfeldová[3,4], Alena Kadlečková[3], Dana Ryšavá[5], Tomáš Velimský[6], Lubomír Ballek[7], Ján Hubač[8], Petr Janský[9], Jana Zvárová[2]

[1]Internal Department, Znojmo Hospital, [2]Center of Biomedical Informatics, Prague, [3]Institute of Computer Science, AS CR, v.v.i, Prague, [4]Internal Department, Čáslav Hospital, [5]Internal Department, Kutná Hora Hospital, [6]Internal Department, Písek Hospital, [7]Internal Department, Jindřichův Hradec Hospital, [8]Internal Department, Chrudim Hospital, [9]Cardiovascular Center, Motol University Hospital, Prague, Czech Republic

Monhart Z[1], Faltus V[2,3], Grünfeldová H[3,4], Kadlečková A[3], Ryšavá D[5],Velimský T[6], Ballek J[7], Hubač J[8], Janský P[9], Zvárová J[2] ([1]Internal Department, Znojmo Hospital, [2]Center of Biomedical Informatics, Prague, [3]Institute of Computer Science AS CR, v.v.i, Prague, [4]Internal Department, Čáslav Hospital, [5]Internal Department, Kutná Hora Hospital, [6]Internal Department, Písek Hospital, [7]Internal Department, Jindřichův Hradec Hospital, [8]Internal Department, Chrudim Hospital, [9]Cardiovascular Center, Motol University Hospital, Prague, Czech Republic). **Reperfusion therapy in ST-segment elevation myocardial infarction – data from a pilot registry of myocardial infarction.** *Cor Vasa 2008;50(2):55–59.*

Aim: To assess utilization of primary reperfusion therapy in patients with acute phase of ST-segment elevation myocardial infarction (STEMI) in the Czech Republic.
Methods: A total of 744 consecutive patients with STEMI from years 2003–2006 were included in the study. Also, data on their demographics and reperfusion strategy were collected. An assessed clinical outcome was in-hospital mortality.
Results: The mean age of STEMI patients was 66.9 ± 12.6 years. The vast majority were men (62.4%). A total of 68.6% STEMI patients received primary reperfusion treatment, 97.0% of them were referred for PPCI and 3.6% were treated with fibrinolytic therapy. Women and elderly patients were less likely to receive reperfusion therapy. The in-hospital mortality was 11.3% for all STEMI patients; 3.5% and 25.7% in the reperfused and non-reperfused groups, ($p < 0.001$). When adjusting for age, the effect of reperfusion therapy remained significant.
Conclusions: In-hospital mortality was significantly reduced in a subgroup of patients who underwent primary reperfusion treatment (PPCI or fibrinolytic therapy). The PPCI represents the entirely prevalent form of reperfusion strategy in the Czech Republic.
Key words: Myocardial infarction – Reperfusion therapy – Mortality

Monhart Z[1], Faltus V[2,3], Grünfeldová H[3,4], Kadlečková A[3], Ryšavá D[5],Velimský T[6], Ballek J[7], Hubač J[8], Janský P[9], Zvárová J[2] ([1]Interní oddělení, Nemocnice Znojmo, [2]Centrum biomedicínckých informací, Praha, [3]Ústav počítačových věd AV ČR, v. v. i., Praha, [4]Interní oddělení, Nemocnice Čáslav, [5]Interní oddělení, Nemocnice Kutná Hora, [6]Interní oddělení, Nemocnice Písek, [7]Interní oddělení, Nemocnice Jindřichův Hradec, [8]Interní oddělení, Nemocnice Chrudim, [9]Kardiovaskulární centrum, Fakultní nemocnice Motol, Praha, Česká republika). **Reperfuzní léčba infarktu myokardu s elevací ST-segmentu – údaje z pilotního registru infarktu myokardu.** *Cor Vasa 2008;50(2):55–59.*

Cíl: Posoudit užitečnost primární reperfuzní léčby u pacientů v akutní fázi infarktu myokardu s elevací ST-segmentu (STEMI) v České republice.
Metoda: Do studie bylo zařazeno celkem 744 po sobě jdoucích pacientů se STEMI v letech 2003–2006. Byly shromážděny i jejich demografické údaje a informace o reperfuzní strategii. Hodnoceným klinickým parametrem byla nemocniční mortalita.
Výsledky: Průměrný věk pacientů se STEMI byl 66,9 ± 12,6 let. V převážné většině se jednalo o muže (62,4 %). Primární reperfuzní léčba byla provedena celkem u 68,6 % pacientů se STEMI, 97,0 % jich bylo indikováno k provedení primární perkutární koronární intervenci (PPCI) a 3,6 % jich bylo léčeno fibrinolýzou. U žen a starších nemocných existovala menší pravděpodobnost, že u nich bude provedena reperfuzní léčba. Nemocniční mortalita u všech pacientů se STEMI dosáhla 11,3 %; z toho 3,5 % ve skupině s reperfuzí a 25,7 % ve skupině bez reperfuze ($p < 0,001$). Po korekci na věk zůstal účinek reperfuzní léčby statisticky významný.
Závěry: V podskupině nemocných, u nichž byla provedena reperfuzní léčba (PPCI nebo fibrinolytická terapie) byla nemocniční mortalita statisticky významně snížena. PPCI je absolutně převládající formou reperfuzní strategie v České republice.
Klíčová slova: Infarkt myokardu – Reperfuzní léčba – Mortalita

Address: MUDr. Zdeněk Monhart, Internal Department, Znojmo Hospital, MUDr. Jana Janského 11, 669 02 Znojmo, Czech Republic, e-mail: monhartz@seznam.cz

**The work was partially supported by project 1M06014 of the Ministry of Education of the Czech Republic.*

INTRODUCTION

Primary reperfusion therapy is the standard of care in acute phase of ST-segment elevation myocardial infarction (STEMI).[1–3] Restoration of flow in the infarct-related artery using fibrinolytic therapy or primary angioplasty (PPCI) improves survival of patients with acute myocardial infarction (MI). The effect on mortality of both fibrinolytic therapy[4] and PPCI[5] has been clearly demonstrated in a number of large clinical trials. However, clinical trials generally include selected populations of patients and/or hospital facilities. National and international registries and databases provide an objective tool to assess the adherence of real-life clinical practice to current guidelines. An important outcome is to evaluate quality of care and to compare medical centres that participated in the registry.[6] Continuous registries can monitor improvement in the quality of care and, consequently, better outcomes over time. Repeated surveys demonstrate increasing proportions of STEMI patients receiving some form of primary reperfusion treatment (56% in the Euro Heart Survey on acute coronary syndromes (EHS-ACS)[7] vs. 64% in the later EHS--ACS.[8] This improvement in therapeutic procedures has reduced the in-hospital mortality of these patients (in-hospital mortality of STEMI patients was 7% in EHS-ACS-2002 and 5.5 % in EHS-ACS-2006).

DESIGN AND METHODS

Our data were obtained from a pilot registry of myocardial infarction (MI) in the years 2003–2004, which covered all cases of patients presenting with acute MI in registry hospitals. The registry hospitals were: Čáslav, Kutná Hora and Znojmo in the years 2003–2006, Jindřichův Hradec and Písek in 2004, and Chrudim in the years 2005–2006. All of them are non-PCI hospitals from geographically different rural regions and collaborate with different PCI centers. Diagnostic criteria for STEMI were: clinical signs of ischemia and persistent ST-segment elevation or presumably new left bundle-branch block on ECG.

STEMI patients represented 28.3% of all patients with MI. We collected data about the patients' characteristics, cardiovascular risk factors and hemodynamic features on presentation. Valid data about the time interval from symptom onset to arrival at hospital were collected only from a minority of patients and therefore these data were not used in statistical analysis. Reperfusion therapy assigned to patients in registry hospitals was assessed in the study, either by transfer to a PCI centre for PPCI or by fibrinolytic therapy. An evaluated clinical outcome was in-hospital mortality.

STATISTICAL METHODS

The data of our interest were the 744 cases of acute ST-elevation MI. Some of the patients – 8 – were observed twice in the time period of the registry (2003–2006). As there is no reason to assume that they would get different health care in comparison with re-infarctions occurring without previous infarction observed in the pilot MI registry, we keep these MIs in the analysis. The second argument to keep these data in the analysis is that it is not always clear whether to exclude the first or later infarction. One reason might be that we often do not know which MI is the first and which (if the second is not known) is the last. Some of the MIs also stay unobserved. Furthermore, the pilot MI registry contains all data without the exact knowledge of a patient's history.

The Kruskall-Wallis test was used to evaluate differences in continuous variables. For evaluating categorical and binary variables, the χ^2 test and logistic regression were used. A p-value of 0.05 was considered to be statistically significant. All calculations along data handling were performed with the system R for statistical computing (version 2.4.0.).

RESULTS

Patient population

The study included 744 patients with diagnosed STEMI – less than one third of all patients with MI present in the myocardial infarction registry. The proportion of STEMI patients was consistent over the four years – 28.1% in 2003, 30.2% in 2004, 25.4% in 2005, and 28.5% in 2006. Among the STEMI patients, the vast majority were men (464/744; 62.4%). The mean age was 66.9 ± 12.6 years; women were older (72.9 ± 10.6 years) than men (63.2 ± 12.3 years). The mean age for all MI patients was older (70.9 ± 12.0 years) than for the STEMI population and patients over 75 years of age accounted for 30.2% (223/744) of STEMI cases, the proportion of elderly patients was higher in women *(Figure 1)*. *Table I* summarizes the demographics of patients in both the reperfusion and non-reperfusion groups. The most frequent cardiovascular risk factor was arterial hypertension (460/711, 64.7%), followed by diabetes (237/705, 33.6%), smoking (233/696, 33.5%) and hyperlipidemia (320/686, 46.6%). Chest pain as a symptom of ischemia was present in 92.4% of the cases (685/741), more often in men (93.7%) than in women (90.3%), p = 0.090. Chest pain was observed less often in patients older than 80 years (86.8%) than in patients younger than 70 years (94.8%), p = 0.009.



Figure 1 Proportions of STEMI patients according to age

Table I
Patients' demographics

	All patients	Reperfusion	No reperfusion	*p*
Number (%)	744 (100.0)	506 (68.7)	231 (31.3)	
Women (%)	280 (37.6)	175 (34.6)	102 (44.2)	0.016
Age, mean ± SD	66.9 ± 12.6	64.7 ± 11.9	71.6 ± 12.7	< 0.001
Age > 75 years (%)	223 (30.2)	115 (22.8)	105 (46.1)	< 0.001
Killip class IV (%)	35 (4.7)	17 (3.4)	14 (6.11)	0.135

p values are calculated between reperfusion and no reperfusion group

Table II
In-hospital mortality according to gender and age group

	All patients	Reperfusion	No reperfusion
Total	11.3%	3.5%	25.7%
Men	9.1%	3.2%	21.7%
Women	14.8%	4.2%	30.7%
p	0.028	0.742	0.163
Age			
< 70	4.2%	2.9%	8.7%
70–80	13.6%	3.9%	30.6%
> 80	31.1%	6.5%	43.8%
p	$p < 0.001$	$p = 0.445$	$p < 0.001$

p values refer to the independence tests for gender or age group and in-hospital mortality

Most of the STEMI patients were in stable hemodynamic state at presentation – 74.9% in Killip class I, 4.7% were in Killip IV.

Reperfusion therapy

A total of 68.6% (506/737) of STEMI patients received primary reperfusion treatment. A total of 97.0% (491/506) of reperfused patients were referred for PPCI to the nearest PCI center and 3.6% (18/506) were treated with fibrinolytic therapy, *Figure 2*. For



Figure 2 Comparison of the use of primary reperfusion therapy in 2003–2005

in-hospital fibrinolysis, the fibrinolytic agent was always streptokinase, pre-hospital fibrinolysis was used in three patients in 2006 and was performed using tenecteplase. Overall, 31.3% (231/737) of patients presenting with STEMI did not receive primary reperfusion therapy – primarily because of extended delay between the onset of chest pain and presentation, the other reasons were advanced age and/or multiple comorbidities.

We observed an improvement in reperfusion strategies in the time period of 2003–2006. The percentage of patients receiving reperfusion therapy increased from 64.5% in 2003 to 75.8% in 2006 ($p = 0.068$).

Women with STEMI received some form of primary reperfusion therapy less likely than men (63.2% vs. 72.0%). The odds ratio (OR) for reperfusion treatment in comparison with men was 0.67 (95% CI: 0.49–0.92), $p = 0.013$. The effect of gender became non-significant when adjusting for age – OR 1.03 (95% CI: 0.73–1.47).

The mean age of patients undergoing reperfusion therapy was significantly lower (64.7 ± 11.9) than in the non-reperfused group (71.6 ± 12.7, $p < 0.001$). As compared with patients under 70 years, the OR for primary reperfusion was 0.64 (95 % CI: 0.44–0.82) for the age group of 70–80 ($p = 0.017$) and 0.20 (95% CI: 0.13–0.30) for the age group of over 80 years ($p < 0.001$), *Figure 3*.

In-hospital mortality

The in-hospital mortality for all STEMI patients was 11.3%, lower in men (9.1%) than in women (14.8%). The mortality rates varied from 9.72% in 2004 to 12.1% in 2006 ($p = 0.91$). Mortality rates differed substantially according to the therapeutic strategy in the acute phase of STEMI. The rate of in-hospital mortality in patients undergoing primary reperfusion treatment (PPCI or fibrinolytic therapy) was 3.5%, the mortality rate for patients without reperfusion therapy was significantly higher – 25.7%, $p < 0.001$. The most substantial differences in the mortality rates according to reperfusion therapy were observed in elderly patients (over 75 years) – 6.3% in reperfused vs. 42.9% in non-reperfused patients,



Figure 3 Primary reperfusion therapy according to age

$p < 0.001$. When comparing reperfused and non-reperfused patients across all age groups, the OR for in-hospital mortality was 0.11 (95% CI: 0.06–0.19), $p < 0.001$. When adjusting for age, the effect of reperfusion therapy remained significant – OR 0.15 (95% CI: 0.08–0.27). *Table II* summarizes the mortality data according to the gender and age group in both the reperfusion and non-reperfusion groups.

However, the most significant predictors for in-hospital mortality proved to be Killip class (increasing), age (increasing) and reperfusion therapy (decreasing). Age of the patients substitutes the effect of gender and smoking.

DISCUSSION

The frequency of reperfusion therapy for STEMI patients varies in different registries. Our reperfusion rate (68.6%) is higher than in EHS–ACS II[8] (64%), even though our patients were older on average. The proportion of reperfused patients in our registry is also higher than in the Italian BLITZ study (65%).[9] The proportion of patients undergoing some form of primary reperfusion therapy was higher in the MINAP database from the UK[10] and in the Vienna STEMI registry[11] than in our study (82.4% and 86.6% respectively), with a substantial participation of fibrinolytic therapy *(Figure IV)*. However, the mean age of patients in the Vienna STEMI registry was lower than in our study (61.8 vs. 66.9 years).



Figure 4 Reperfusion strategies in patients with STEMI

When comparing our results with available data from the Czech Republic, there are two registries of the last few years. In the South Bohemian Coronary Registry, 79% of STEMI patients were treated with primary reperfusion treatment[11] and the recently published CZECH registry showed a similar incidence in its "regional" arm (80%).[12] Both these registries demonstrated a higher incidence of primary reperfusion therapy than in our registry (68.6%). However, in both these cases, reperfusion therapy was evaluated in well-defined regions attached to one umbrella PCI centre. In contrast to the CZECH registry, the data in our pilot MI registry have been collected since 2003. This could be the reason for the discrepancy in the proportion of patients receiving primary reperfusion treatment – in our cohort, we showed an increase of reperfusion rates in the time period of 2003–2006. The proportion of STEMI patients eligible for primary reperfusion supposedly had a limit value related to the number of patients presenting in more than 12 hrs after onset of symptoms.[14,15] The in-hospital mortality for all STEMI patients (independent of the therapy provided in acute phase) was similar in our pilot registry and in the other registries (11.3% vs. 9.5% in the Vienna STEMI registry and 11.3% vs. 11.8% in the MINAP registry). In reperfused patients, the in-hospital mortality rate was lower in our study (3.5%) than in comparable registries (6.7% in the CZECH registry[13]; 8.2% in the Vienna STEMI registry[11]; 6.7% in the Italian VENERE registry[16]) and, in the non-reperfused group, our mortality rates were higher (25.7% vs. 18.4% in the Vienna STEMI registry).

Limitations of the study

Data in our study originated from a pilot myocardial infarction registry in a few regions of the Czech Republic and were collected retrospectively from patients' records. Thus we have to admit that some of the data were incomplete because there was no system of data quality control (at least not such as there are in clinical trials). We were unable to obtain the entire information about the number of patients who underwent CABG after angiography – these data are available from the PCI registry. However, the primary purpose of our study was to evaluate the quality of care in non-PCI hospitals – particularly the percentage of STEMI patients treated with primary reperfusion treatment.

CONCLUSIONS

We evaluated the utilization of reperfusion therapy in patients with acute phase of STEMI in real-life practice. In the Czech Republic, primary angioplasty represents the entirely prevalent form of reperfusion strategy. Increased delivery of primary reperfusion is the most efficient way to reduce in-hospital mortality of STEMI patients. Primary reperfusion therapy offered a significant survival advantage even in patients with

advanced age compared to those in whom such a therapy was omitted.

REFERENCES

1. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28–66.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST--elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44:E1–E211.
3. Widimsky P, Janousek S, Vojacek J. Guidelines for the management of ST-elevation myocardial infarction. Cor Vasa 2002;44:K123–K143.
4. Maggioni AP, Franzosi MG, Fresco C, et al. GISSI trials in acute myocardial infarction. Rationale, design, and results. Chest 1990;97(4 Suppl):146S–150S.
5. Widimský P, Groch L, Zelízko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000;21: 823–31.
6. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006;295:1912–20.
7. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterean basin. The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J 2002;23:1190–201.
8. Mandelzweig L, Battler A, Boyko V, et al. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J. 2006;27:2285–93.
9. Di Chiara A, Chiarella F, Savonitto S, et al. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003;24:1616–29.
10. Birkhead JS, Weston C, Lowe D. Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-5: observational study. Br Med J 2006;332:1306–11.
11. Kalla K, Christ G, Karnik R, et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006;113:2398–405.
12. Tousek F, Jelinek P, Vacha M, et al. Treatment of ST-elevation myocardial infarction in the heart of Europe: analysis of the South Bohemian Coronary Registry. Interv Akut Kardiol 2004;3:181–4.
13. Widimsky P, Zelizko M, Jansky P, Tousek F, Holm F, Aschermann M; CZECH investigators. The incidence, treatment strategies and outcomes of acute coronary syndromes in the „reperfusion network“ of different hospital types in the Czech Republic: results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. Int J Cardiol 2007;119:212–9.
14. Cohen M, Gensini GF, Maritz F, et al. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial. Circulation 2003;108 (16 Suppl 1):III14–III21.
15. Terkelsen CJ, Lassen JF, Nørgaard BL, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J 2005;26:18–26.
16. Di Pede F, Olivari Z, Schievano E, et al. Impact of reperfusion strategies on in-hospital outcome in ST-elevation myocardial infarction in a context of interhospital network: data from the prospective VENERE registry (VENEto acute myocardial infarction REgistry. Ital Heart J Suppl 2005;6:804–11.

Received 5 September 2007
Revision accepted 19 November 2007